In a 5-year clinical study, men treated with PROPECIA reported...

"My expectations coming in were to keep the same head of hair that I have, without losing any more hair. Today, it's pretty much the same. It's working, and I'm comfortable with where I'm at right now."

— Blake Stallings, PROPECIA user

...their bald spot getting smaller.¹

"I wasn't expecting regrowth, I was just expecting maintenance. I was impressed."

— Michael Corbo, PROPECIA user

...improvement in the appearance of their hair.¹

"I was just hoping to maintain what I had, but it's actually thickened up. There's black hair back there... probably a few grays too. Just like what I had before. It's great – that's exactly what I was looking for."

— Alan Wing, PROPECIA user

...increased hair growth.¹

"My original goal was to keep what I had and just be happy with that, but my friends started to notice that it was filling in... I'm amazed that it works so well for me."

— Wallace Tablit, PROPECIA user

...a slowing of their hair loss.¹

"I got more than what I expected. People notice the difference."

— Manuel Beauchamp, PROPECIA user

...greater overall satisfaction with their hair compared to men treated with placebo¹

"I would recommend it. I should’ve taken action a long time ago."

— Manuel Beauchamp, PROPECIA user

...greater satisfaction with their frontal hairline compared to men treated with placebo¹

"If I tell people that I’m using it, they say, ‘Your hair’s fine, why would you be using it?’ I tell them that it’s fine because I am using it."

— Michael Corbo, PROPECIA user

...greater satisfaction with the appearance of the hair on the top of their head¹

PROPECIA is the first oral therapy indicated for the treatment of male pattern hair loss in MEN ONLY. Safety and efficacy were demonstrated in men, aged 18 to 41, with mild to moderate hair loss of the vertex and anterior mid-scalp area. Efficacy in bitemporal recession has not been established.

PROPECIA is not indicated in women or children.

Important Safety Information

PROPECIA is contraindicated in women when they are or may potentially be pregnant. Finasteride may cause abnormalities of the external genitalia of a male fetus of a pregnant woman.

PROPECIA is contraindicated in patients with hypersensitivity to any component of this medication.

Women should not handle crushed or broken PROPECIA tablets when they are pregnant or may potentially be pregnant because of the possibility of absorption of finasteride and the subsequent potential risk to a male fetus. PROPECIA tablets are coated and will prevent contact with the active ingredient during normal handling, provided that the tablets have not been broken or crushed.

Caution should be used in patients with liver function abnormalities, as finasteride is metabolized extensively in the liver.

Physicians should instruct their patients to promptly report any changes in their breasts such as lumps, pain, or nipple discharge. Breast changes including breast enlargement, tenderness, and neoplasm have been reported.

In clinical studies with finasteride 1 mg in men aged 18 to 41, the mean value of serum prostate-specific antigen (PSA) decreased from 0.7 ng/mL at baseline to 0.5 ng/mL at month 12. In clinical studies with PROSCAR^® (finasteride, 5 mg) when used in older men who have benign prostatic hyperplasia (BPH), PSA levels are decreased by approximately 50%. These findings should be taken into account for proper interpretation of serum PSA when evaluating men treated with finasteride.

In clinical studies of 1 year for PROPECIA, each drug-related sexual adverse event occurred in less than 2% of men. Discontinuation due to drug-related sexual adverse experiences was 1.2% in the group treated with PROPECIA and 0.9% in the placebo-treated group. Reported drug-related sexual adverse experiences included decreased libido (1.8% vs 1.3%, placebo), erectile dysfunction (1.3% vs 0.7%, placebo), and ejaculation disorders (1.2% vs 0.7%, placebo), primarily decreased volume of ejaculate (0.8% vs 0.4%, placebo). Resolution occurred in the 1-year studies in men who discontinued therapy with PROPECIA due to these sexual side effects. The incidence of each of the above side effects decreased to ≤0.3% by the fifth year of treatment with PROPECIA.

In postmarketing experience, the following adverse events have been reported: breast tenderness and enlargement; hypersensitivity reactions including rash, pruritus, urticaria, and swelling of the lips and face; and testicular pain.

If PROPECIA has not maintained hair count or regrown visible hair within 12 months, further treatment is unlikely to be of benefit. Withdrawal of treatment leads to reversal of effect within 12 months.

No dosage adjustment is necessary in the elderly or in patients with renal insufficiency.

Before prescribing PROPECIA, please read the Prescribing Information. The Patient Information also is available.